31.01.2018
4SC: Positive DSMB safety review of 4SC’s pivotal RESMAIN study of resminostat in CTCL
25.01.2018
Nanogate SE Expects 2018 Operating Result (EBITDA) of More Than EUR 24 Million and Sales of at Least EUR 220 Million
22.01.2018
4SC AG strengthens patent protection for its Hedgehog/GLI signaling inhibitor 4SC-208
10.01.2018
Nanogate SE: Market Launch of New Technology Platform to Replace Stainless Steel
20.12.2017
4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
20.11.2017
Nanogate SE Intends to Continue its Course of Expansion With Further Acquisition and to Extend its Global Market Position
06.11.2017
4SC: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma
10.10.2017
4SC: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
28.09.2017
Nanogate SE improves its margin in the first half of the year and expects sales of over EUR 250 million over the medium term
13.09.2017
4SC: Phase I study of 4SC’s resminostat indicates efficacy in biliary tract cancer
04.02.2016
Nanogate driving international growth forward – Strong foreign business expected for 2016
21.01.2016
vasopharm Announces EUR 20 million Fundraising to Progress Treatment for Traumatic Brain Injury
23.04.2015
Nanogate plans to increase sales to over EUR 80 million – Preliminary figures for 2014 exceeded
09.04.2015
Nanogate expands technology portfolio: creation of a new platform for the multifunctional metallisation of surfaces
19.01.2015
Nanogate AG opens up new field of application with a major order for touchpads
06.11.2014
4SC announces financial results for the first nine months and the third quarter of 2014
24.09.2014
Nanogate generates sales increase – Operating result improves disproportionately – Order base increased
10.09.2014
Nanogate AG: Growth offensive on innovative metal coatings – establishment of a centre of excellence for the advanced metals division
10.07.2014
Nanogate AG acquires surface specialist Vogler: expansion of technology portfolio and capacities
26.05.2014
MerLion Announces a Significant Milestone in the Development of Finafloxacin for Treatment of Acute Otitis Externa
26.02.2014
Nanogate achieves over EUR 50 million in sales and launches strategy programme with a sales target of EUR 100 million
22.10.2013
vasopharm Reports Endorsement of Phase III Trial Design in Traumatic Brain Injury by European Medicines Agency
30.09.2013
NANOGATE AG: SALES INCREASED BY ALMOST A THIRD, CONSOLIDATED NET INCOME DOUBLED
03.09.2013
NANOGATE AG: MASS PRODUCTION BEGINS ON SIX DIFFERENT GLAZING COMPONENTS FOR A NEW PREMIUM SUV
16.07.2013
NANOGATE ESTABLISHES ITSELF AS A SYSTEMS SUPPLIER (TIER 1 SUPPLIER) FOR A LEADING GLOBAL AUTOMOBILE MANUFACTURER WITH A MAJOR ORDER FOR HIGH-QUALITY PLASTICS
01.07.2013
Nanogate AG equips industrial facilities with high-performance filter systems
30.06.2013
HeidelbergCapital and Entrepreneurs Fund lead the takeover of the stake of EMBL Technology Fund in vasopharm GmbH
05.06.2013
Nanogate expands structure for strategic growth field of glazing and secures new orders
14.03.2013
Another record year of sales and earnings for Nanogate – EBITDA increased to around EUR 5.6 million
05.03.2013
Nanogate AG: Production of glazing components under way for premium German manufacturer – Biggest order in the company’s history
18.12.2012
Nanogate will supply technology for the global leader in variable focus eyewear
11.12.2012
MerLion Pharmaceuticals Announces Initiation of first Phase II Clinical Study with Finafloxacin in Patients with Complicated Urinary Tract Infections
08.11.2012
Nanogate acquires equity holding in plastics specialist Plastic-Design – Considerable growth expected in dynamic market for glazing systems with high-tech plastics
07.11.2012
MerLion Announces Successful Completion of a Phase I Clinical Study with Intravenously Administered Finafloxacin
25.09.2012
Dynamic growth for Nanogate AG: EBIT nearly trebled, forecast for 2012 confirmed
17.09.2012
vasopharm’s Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial
18.04.2012
MerLion Announces Initiation of a Phase III Clinical Programme to Evaluate Finafloxacin for the Treatment of Acute Otitis Media
19.01.2012
4SC AG: Cancer compound resminostat meets primary endpoint in Phase II trial in advanced liver cancer ahead of schedule